European Archives - Page 6 of 1311 - European Medical Journal

The New Frontiers of Personalised Cancer Prevention

THIS YEAR, the highly anticipated European Society for Medical Oncology (ESMO) Congress 2025 was held in Berlin, Germany…

Multi-omics Insights for Biomarkers in NSCLC

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality worldwide…

Immune Checkpoint Inhibitor-Associated Hydropneumothorax

Immune checkpoint inhibitors (ICI) are monoclonal antibodies capable of reversing cancer-induced immune evasion and promoting tumour death…

Recurrent Plexiform Neurofibroma with KRAS and AKT1 Mutations

Plexiform neurofibromas (PNF) are benign, often infiltrative tumours of the peripheral nerve sheath classically linked to neurofibromatosis…

Favorable Response of Unresectable Giant Pinealoblastoma

The pineal gland is a small endocrine gland that regulates the circadian rhythm by secreting melatonin. Tumours of the pineal region…

CAR-T Cell Immunotherapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic modalities such as…

Aggressive Vulvar Angiomyxoma in Term Pregnancy

Aggressive angiomyxoma (AA) is a rare, slow-growing, but locally infiltrative mesenchymal tumour primarily affecting women of…

Vaccine

Europe’s vaccine pipeline has 91 candidates in R&D

Crucially, 41% of these candidates target pathogens for which no vaccines or prophylactic monoclonal antibodies are currently registered.

Body Dysmorphic Disorder Beyond the Skin

In this series, host Catherine Glass speaks with Katharine Phillips to explore body dysmorphic disorder beyond the skin.

PCSK9

Statins and Emerging PCSK9 Therapies Under Spotlight in Liver Disease Management

A new review finds statins remain safe and effective in MASLD, while evidence for PCSK9 inhibitors is promising but still limited.